Artificial Intelligence for Drug Discovery and Development Market Size & Share by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Artificial Intelligence for Drug Discovery and Development Market Size Analysis

Global Artificial Intelligence for Drug Discovery and Development Market Introduction
By Application
1. Introduction
  1. By Application By Value
2. Drug optimisation and repurposing
  1. By Value
3. Preclinical testing
  1. By Value
4. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Neurodegenerative Diseases
  1. By Value
4. Infectious Disease
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology
  1. By Value
3. CRO
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Application
1. Introduction
  1. By Application By Value
2. Drug optimisation and repurposing
  1. By Value
3. Preclinical testing
  1. By Value
4. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Neurodegenerative Diseases
  1. By Value
4. Infectious Disease
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology
  1. By Value
3. CRO
  1. By Value
4. Others
  1. By Value
U.S.
1. By Application
  1. Introduction
    1. By Application By Value
  2. Drug optimisation and repurposing
    1. By Value
  3. Preclinical testing
    1. By Value
  4. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Neurodegenerative Diseases
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology
    1. By Value
  3. CRO
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Application
1. Introduction
  1. By Application By Value
2. Drug optimisation and repurposing
  1. By Value
3. Preclinical testing
  1. By Value
4. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Neurodegenerative Diseases
  1. By Value
4. Infectious Disease
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology
  1. By Value
3. CRO
  1. By Value
4. Others
  1. By Value
U.K.
1. By Application
  1. Introduction
    1. By Application By Value
  2. Drug optimisation and repurposing
    1. By Value
  3. Preclinical testing
    1. By Value
  4. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Neurodegenerative Diseases
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology
    1. By Value
  3. CRO
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Application
1. Introduction
  1. By Application By Value
2. Drug optimisation and repurposing
  1. By Value
3. Preclinical testing
  1. By Value
4. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Neurodegenerative Diseases
  1. By Value
4. Infectious Disease
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology
  1. By Value
3. CRO
  1. By Value
4. Others
  1. By Value
China
1. By Application
  1. Introduction
    1. By Application By Value
  2. Drug optimisation and repurposing
    1. By Value
  3. Preclinical testing
    1. By Value
  4. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Neurodegenerative Diseases
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology
    1. By Value
  3. CRO
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Application
1. Introduction
  1. By Application By Value
2. Drug optimisation and repurposing
  1. By Value
3. Preclinical testing
  1. By Value
4. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Neurodegenerative Diseases
  1. By Value
4. Infectious Disease
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology
  1. By Value
3. CRO
  1. By Value
4. Others
  1. By Value
UAE
1. By Application
  1. Introduction
    1. By Application By Value
  2. Drug optimisation and repurposing
    1. By Value
  3. Preclinical testing
    1. By Value
  4. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Neurodegenerative Diseases
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology
    1. By Value
  3. CRO
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Application
1. Introduction
  1. By Application By Value
2. Drug optimisation and repurposing
  1. By Value
3. Preclinical testing
  1. By Value
4. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Neurodegenerative Diseases
  1. By Value
4. Infectious Disease
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology
  1. By Value
3. CRO
  1. By Value
4. Others
  1. By Value
Brazil
1. By Application
  1. Introduction
    1. By Application By Value
  2. Drug optimisation and repurposing
    1. By Value
  3. Preclinical testing
    1. By Value
  4. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Neurodegenerative Diseases
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology
    1. By Value
  3. CRO
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Artificial Intelligence for Drug Discovery and Development Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Alphabet Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Atomwise Inc.
Benevolent AI
Cloud Pharmaceutical
Deep Genomics
Exscientia
IBM Corporation
Insilico Medicine Inc.
Microsoft Corporation
Nvidia Corporation.
GNS Healthcare
Google (DeepMind)
BioSymetrics, Inc.
Berg Health

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment